456 Studies Now Enrolling
A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu PositiveSubjects with Residual Disease or High-Risk PCR after both Neoadjuvant andPostoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01)
Study of GLSI-100 in Female Patients with Breast Cancer
| Sponsor: | Greenwich Lifesciences, Inc. |
| Enrolling: | Female Patients Only |
| IRB Number: | AAAU0138 |
| U.S. Govt. ID: | NCT05232916 |
| Contact: | Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu |
Additional Study Information:
The purpose of this research is to test how well an investigational study drug (medication), GLSI-100, can prevent your cancer from coming back. The research study will also collect information about the safety of the medication. The research will also study how the medication works and who responds the best to the medication. GLSI-100 is a combination of a study medication called GP2 and the FDA-approved medication, granulocyte-macrophage colony-stimulating factor (GM-CSF) or sargramostim (Leukine). It is thought that this medication will work by helping your immune system identify and remove cancer cells.
